Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management

Immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) are a standard of care for advanced melanoma. Novel toxicities comprise immune-related adverse events (irAE). With increasing use, irAE require recognition, practical management strategies, and multidisciplinary care. We retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lomax, Anna J., Lim, Jennifer, Cheng, Robert, Sweeting, Arianne, Lowe, Patricia, McGill, Neil, Shackel, Nicholas, Chua, Elizabeth L., McNeil, Catriona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828308/
https://www.ncbi.nlm.nih.gov/pubmed/29610684
http://dx.doi.org/10.1155/2018/9602540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828308/
https://www.ncbi.nlm.nih.gov/pubmed/29610684
http://dx.doi.org/10.1155/2018/9602540

Ejemplares similares